SIGN UP

March 27, 2018 09:07 AM EDT

Lies, damn lies and statistics: A Stanford wiz says P<0.05 offers deceptive evidence of biopharmas' drug claims

The biopharma R&D world revolves around one simple formula: A P value of less than 0.05 in a pivotal study. But a top professor of …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE

TRENDING NOW

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

sponsored

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?